Back to top
more

Annovis Bio (ANVS)

(Real Time Quote from BATS)

$2.67 USD

2.67
117,571

-0.01 (-0.37%)

Updated Aug 5, 2025 03:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Novo Nordisk (NVO) Up on Positive Kidney Outcomes Study Update

by Zacks Equity Research

Novo Nordisk (NVO) is set to stop its kidney outcomes study on Ozempic based on interim analysis results that met certain pre-specified efficacy criteria for early closure. The stock rises 5.2%.

Zacks Equity Research

Alnylam (ALNY) Receives CRL for the Label Expansion of Onpattro

by Zacks Equity Research

Alnylam's (ALNY) label expansion-seeking application for Onpattro, to treat transthyretin-mediated amyloidosis with cardiomyopathy, gets the FDA's CRL on the grounds of insufficient data. The stock falls 5%.

Zacks Equity Research

Coherus (CHRS) Stock Rises on BLA Re-Filing for Udenyca Onbody

by Zacks Equity Research

Coherus (CHRS) resubmits biologics license application for Udenyca Onbody, an on-body injector presentation of Udenyca to the FDA. Stock rises.

Zacks Equity Research

Arcutis (ARQT) Up on FDA Nod for Zoryve Label Expansion

by Zacks Equity Research

Arcutis (ARQT) gains on receiving FDA approval for label expansion of Zoryve (roflumilast) cream 0.3% to treat patients in the age group of 6-11 years with plaque psoriasis.

Zacks Equity Research

Merck's (MRK) Meets Goal in Muscle-Invasive Bladder Cancer Study

by Zacks Equity Research

Data from a late-stage study shows that Merck's (MRK) Keytruda lowered the risk of disease recurrence or death when used after surgery in certain patients with urothelial carcinoma.

Zacks Equity Research

Apellis (APLS) Provides Syfovre Q3 Preliminary Revenues Guidance

by Zacks Equity Research

Apellis' (APLS) shares rise as it provides third-quarter 2023 preliminary revenues guidance for Syfovre, approved for the treatment of geographic atrophy.

Zacks Equity Research

Orchard (ORTX) Up 97% on $478M Acquisition Deal With Kyowa Kirin

by Zacks Equity Research

Orchard (ORTX) is set to be acquired by Kyowa Kirin for a consideration of $17 per American Depositary Share, which amounts to a total transaction value of approximately $478 million. Shares rise 97%.

Zacks Equity Research

ALX Oncology (ALXO) Up 56% on Upbeat Gastric Cancer Study Data

by Zacks Equity Research

Interim data from a mid-stage study shows that a combination regimen of ALX Oncology's (ALXO) lead candidate achieved 52% ORR in certain gastric cancer patients.

Zacks Equity Research

Kezar (KZR) Falls 10% on Strategic Update, Reduces Workforce

by Zacks Equity Research

Kezar (KZR) falls 10% on the decision to channel resources to one clinical candidate as part of its reprioritization efforts and slash the workforce by 41%.

Zacks Equity Research

Intellia (NTLA), Regeneron Expand Deal for Gene-Editing Therapies

by Zacks Equity Research

Intellia (NTLA) expands partnership with Regeneron, to develop potential treatments for neurological and muscular diseases.

Zacks Equity Research

Sanofi (SNY) Inks Deal With J&J to Develop E. coli Vaccine

by Zacks Equity Research

Per the terms of the deal, Sanofi (SNY) and J&J will co-fund current and future R&D costs to develop a potential first-in-class vaccine against extraintestinal pathogenic E. coli.

Zacks Equity Research

Apellis' (APLS) Empaveli Injector Gets FDA Nod for PNH

by Zacks Equity Research

Apellis (APLS) receives the FDA approval for Empaveli Injector, a self-administred on-body device, to treat patients with paroxysmal nocturnal hemoglobinuria.

Zacks Equity Research

NRx Pharma (NRXP) to Initiate Clinical Study on NRX-101, Stock Up

by Zacks Equity Research

NRx Pharma (NRXP) receives FDA clearance to begin clinical development for its lead candidate, NRX-101, to treat chronic pain.

Zacks Equity Research

Karuna (KRTX) Submits NDA Filing to FDA for Schizophrenia Drug

by Zacks Equity Research

If approved, Karuna's (KRTX) KarXT will be the first new mechanism of action to treat schizophrenia in several decades. Data from three clinical studies support the FDA filing.

Zacks Equity Research

Amicus (FOLD) Gets FDA Approval for Pompe Disease Drug

by Zacks Equity Research

Amicus (FOLD) receives approval for Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) from the FDA to treat the adult late-onset Pompe disease.

Zacks Equity Research

Nektar (NKTR), Cellular Biomedicine Join for Lung Cancer Studies

by Zacks Equity Research

Nektar (NKTR) enters into a deal with Cellular Biomedicine Group to develop NKTR-255 in combination with C-TIL05 to treat advanced NSCLC.

Zacks Equity Research

Biohaven (BHVN) Up on Positive Data from Autoimmune Disease Drug

by Zacks Equity Research

Biohaven (BHVN) gains on preliminary data from a pre-clinical study on its pipeline candidate BHV-1300 targeting various autoimmune diseases.

Zacks Equity Research

Soleno (SLNO) Soars as Prader-Willi Syndrome Study Meets Goal

by Zacks Equity Research

Soleno's (SLNO) shares rally as the late-stage study evaluating diazoxide choline for patients with Prader-Willi syndrome meets its primary and secondary endpoints.

Zacks Equity Research

Repligen (RGEN) to Acquire Fluid Management Company Metenova

by Zacks Equity Research

Repligen (RGEN) is set to acquire a Swedish company, Metenova, which focuses on manufacturing magnetic mixers for pharmaceutical and biotechnology applications.

Zacks Equity Research

Biophytis (BPTS) Soars 73% on Partnership With Skyepharma

by Zacks Equity Research

Biophytis (BPTS) gains on signing a partnership with Skyepharma, for the production of regulatory batches of its lead candidate, Sarconeos (BIO101).

Zacks Equity Research

Merck (MRK), Eisai Combo Therapy Fail Two Lung Cancer Studies

by Zacks Equity Research

Data from both late-stage studies evaluating Merck's (MRK) Keytruda and Eisai's Lenvima combination in certain types of metastatic non-small cell lung cancer, fail to achieve their primary endpoints.

Zacks Equity Research

FDA Expands Lilly (LLY) Jardiance Label in Chronic Kidney Disease

by Zacks Equity Research

Following the latest approval, Lilly's (LLY) Jardiance can access a target market that affects more than 35 million adults in the United States.

Zacks Equity Research

Travere (TVTX) Slumps 41% on Mixed Results From IgAN Drug Study

by Zacks Equity Research

Data from a confirmatory study shows that Travere's (TVTX) IgAN therapy did not achieve one of its confirmatory secondary endpoints. This will likely hurt the company's chances for the drug's full approval.

Zacks Equity Research

Jazz Pharma (JAZZ) Gets EU Nod for Cancer Drug Enrylaze

by Zacks Equity Research

The approval is based on data from a phase II/III study, which showed that treatment with Jazz's (JAZZ) Enrylaze achieved sustained asparagine activity in two cancer indications.

Zacks Equity Research

Puma's (PBYI) Alisertib Gets FDA's Orphan Drug Tag for SCLC

by Zacks Equity Research

Puma's (PBYI) alisertib receives the Orphan Drug designation from the FDA for treating patients with small cell lung cancer.